“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Figures & data

Figure A1. Cutaneous immune-related adverse events usually reported as “skin rash”: A maculopapular rash; B lichenoid reaction; C psoriatic rash; D neutrophilic rash; E Grover’s disease.

Figure A2. Management of patient with immune-related skin rash and specific suggestions based on type of irCAE.

Abbreviations: irCAE immune-related cutaneous adverse event; MTX methotrexate; MPR maculopapular rash, SRL sarcoidosis like reaction; ICI immune-checkpoint inhibitor

Figure A3. A Lichenoid-like changes with superficial perivascular T-cell infiltrate (hematoxylin-eosin stain, 10X magnification); B marked spongiosis, lymphocytic infiltrate at the papillary dermis with eosinophils and epidermal orthokeratosis (hematoxylin-eosin stain, 20X magnification).